Here are the 424B prospectus supplements from Travere Therapeutics, Inc. (TVTX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVTX filings page.
Travere Therapeutics is offering $475,000,000 aggregate principal amount of 0.50% convertible senior notes due 2032, with an underwriter option for an additional $50,000,000. The notes pay 0.50% interest, mature on May 15, 2032, and have an initial conversion rate of 15.4078 shares per $1,000 (approximate conversion price $64.90 per share). Conversions are permitted only upon specified stock-price, note-trading-price, corporate-event or redemption conditions and, if converted, will be settled in cash, shares or a combination at the company’s election. Travere expects to use a portion of net proceeds to repurchase part of its 2.25% convertible senior notes due 2029 and the remainder for general corporate purposes. The offering is not intended to be listed and settlement is expected on or about May 11, 2026.
Travere Therapeutics is offering $400,000,000 aggregate principal amount of % convertible senior notes due 2032, with an underwriter option for up to $60,000,000 additional notes, subject to completion. The notes mature on May 15, 2032, bear stated cash interest (rate not specified in the excerpt) payable semi-annually, and are convertible into cash, shares of common stock or a combination at Travere’s election under specified conditions.
Conversion is permitted only upon specified triggers including a sustained common-stock price condition, a note trading-price test, certain corporate events, a call for redemption and during a conversion period beginning February 17, 2032. Notes are redeemable at Travere’s option on or after May 21, 2029 if Nasdaq trading thresholds are met. The notes will be unsecured senior obligations and will rank equal with other unsecured indebtedness and be structurally subordinated to subsidiaries’ liabilities. Travere does not intend to list the notes; its common stock traded at $44.91 on May 4, 2026. This prospectus supplement is preliminary and subject to completion (dated May 5, 2026).